REG - Genflow Biosciences - Two Non-Dilutive Research Grant Awards

Genflow BiosciencesAnnouncement

18/01/2024 12:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240118:nRSR1848Aa&default-theme=true

RNS Number : 1848A  Genflow Biosciences PLC  18 January 2024

 

18 January 2024

 

Genflow Biosciences Plc

 

("Genflow" or "the Company")

 

Secures Two Research Grants from Belgium's New Technological Innovation
Partnership

 

The Company (LSE:GNF) (OTCQB:GENFF), an emerging leader in the field of
longevity research developing therapeutics that potentially halt or slow the
ageing process is pleased to announce two significant new research programs in
collaboration with Revatis SA and EXO Biologics, backed by substantial
non-diluting and non-reimbursable research grants by the Government of
Wallonia in Belgium. Funding for the two research programs, as part of the
Wallonia Recovery Plan by the Walloon Government in Belgium, will be disbursed
annually to the Company, contingent upon Genflow and its collaborators
achieving specific, activity-based milestones. Continued receipt of the grants
by Genflow is dependent on the parties meeting predefined criteria each
applicable year.

 

Technological Innovation Partnership (ATMP)

 

The two research programs are a part of a broader innovation partnership that
the Walloon Government has launched, dedicated to Advanced Therapy Medicinal
Products (ATMPs). The partnership boasts a substantial budget of 81 million
euros, a mix of 60% public funding and 40% private contributions from various
companies, spread over three years. This initiative is a collaborative effort
involving BioWin, the Health Cluster of Wallonia and the Public Service of
Wallonia, representing a significant commitment to advancing medical research
and development in the region.

 

Sarcopenia Research Program with Revatis SA

 

Genflow, together with Revatis SA, has launched a 3-year sarcopenia research
program, generously funded by a grant totalling 1.34 million euros.
Sarcopenia, the progressive loss of muscle mass and function associated with
ageing, poses a significant health risk and affects the quality of life for
millions of elderly people worldwide. This collaborative effort aims to expand
and diversify Genflow's research pipeline, addressing this growing concern as
the global population ages. The partnership will leverage both companies'
expertise to develop innovative solutions and contribute valuable insights
into the mechanisms of age-related muscle deterioration.

 

mRNA Delivery Research with EXO Biologics

 

Genflow and EXO Biologics have initiated a 3-year scientific program,
supported by a grant of 1.55 million euros. The project focuses on the
development of a novel mRNA delivery system using exosomes to encapsulate and
transport Genflow's proprietary centenarian SIRT6 gene. This cutting-edge
approach aims to harness the natural advantages of exosomes, such as enhanced
stability, improved cellular uptake, reduced immunogenicity, minimal toxicity,
natural cargo sorting and reduced off-target effects, among others. This
endeavour not only demonstrates Genflow's momentum in leading-edge research,
but also holds the potential to revolutionize therapeutic interventions for
Werner Syndrome, an accelerated ageing condition and holds great promised for
a range of other age-related conditions.

 

Dr. Eric Leire, CEO of Genflow commented: "We are excited to embark on this
exciting new research, which aligns with our quest to understand and alleviate
the impacts of ageing. Launching both of these programs represents a strategic
move to enhance our research capabilities, while contributing to the
understanding of age-related conditions. Both of these strategic initiatives
will strengthen Genflow's position at the forefront of ageing-related
research, and its mission to improve the health and well-being of older
adults."

 

The information communicated in this announcement is inside information for
the purposes of Article 7 of Regulation 596/2014.

 

For further information please contact:

 

 Genflow Biosciences Plc
 Dr Eric Leire              +32 477 495 881

 Chief Executive Officer

 Clear Capital Markets
 Joint Corporate Broker     +44 203 869 6080

 Bob Roberts

 Capital Plus Partners Ltd
 Joint Corporate Brokers

 Dominic Berger             +44 203 821 6167

 Keith Swann                +44 0203 821 6169

 Jon Critchley              +44 0203 821 6168
 Harbor Access
 Investor Relations         +1-475-477-9401

 Jonathan Paterson

 

About Genflow Biosciences

 

Established in 2020, Genflow Biosciences Ltd is a UK-based biotechnology
company, with R&D facilities in Belgium, developing and researching
potential novel therapeutics that halt or slow the ageing process enabling
society to live longer, healthier lives. Genflow Biosciences lead compound is
GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene
which has yielded promising preclinical results. Genflow Biosciences expects
to commence a clinical trial in 2024 to study the potential benefit of GF-1002
in non-alcoholic steatohepatitis (NASH) for which there are few or no-approved
therapies. By treating ageing as a risk factor to disease, Genflow Biosciences
aims to reduce the financial, emotional, and social costs of an ageing
population.

 

For more information: www.genflowbio.com (http://www.genflowbio.com/)

 

About Revatis SA

 

Revatis SA is a biotechnology firm based in Luxemburg specializing in the
collection, production and storage of autologous muscle-derived mesenchymal
stem cells (MdMSC) for immediate therapeutic use or storage for further
processing. RevaTis technology is minimally invasive and offers benefits for
generating a large number of autologous stem cells. Their expertise in
sarcopenia research makes them a valuable partner in addressing muscle
deterioration in the elderly.

 

For more information: www.revatis.com (http://www.revatis.com/)

 

About EXO Biologics

 

EXO Biologics is Belgian biotech company committed to developing
biopharmaceuticals using Extracellular Vesicles (EVs). Their work in mRNA
encapsulation and delivery is revolutionizing the approach to genetic and
cellular therapies.

 

For more information: www.exobio.be (http://www.exobio.be/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDGZGMMZRZGDZM